Jun 28 |
Carisma jumps as drug discovery under Moderna deal leads to $2M payment
|
Jun 27 |
Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
|
Jun 26 |
Carisma Therapeutics’ solid tumour therapy obtains FDA Fast Track status
|
Jun 25 |
Carisma Therapeutics granted FDA fast track designation for its solid tumors treatment
|
Jun 25 |
Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum
|
Jun 25 |
Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors
|
Jun 13 |
Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders
|
May 30 |
Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference
|
May 16 |
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte
|
May 14 |
Is There An Opportunity With Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 46% Undervaluation?
|